[29] examined treatment resistance in IIH (defined by authors as composite of indicators including requirement for escalation of medical therapy, progression to surgical intervention, need for CSF diversion procedures, or optic nerve decompression or sheath fenestration)) and noted a trend toward fewer refractory cases with tirzepatide (20.5% risk reduction, RR 0.795, p = 0.019 at 24 months)
After the test results are examined and the patient is deemed suitable for the treatment, an intravenous line is opened where the components of the serum are given to the patient for 15-20 minutes
Advise on monitoring hormonal profile changes and metabolic outcomes throughout GLP-1 therapy in fertility patients Check monthly pregnancy tests, weight, fast glucose, HbA1c, and lipid profile
The 28% triglyceride reduction, 6.8 mmHg blood pressure drop, and superior weight loss all suggest cardiovascular benefits that may exceed the competitors